Study of tagraxofusp reports 90 percent response rate for deadly blood cancer with no prior available therapies
An open-label, multi-cohort Phase II trial, led by investigators at The University of Texas MD…
Browsing: tagraxofusp
An open-label, multi-cohort Phase II trial, led by investigators at The University of Texas MD…